NCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
71 trialsNCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03199885 2025-12-30
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02115282 2025-12-18
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01275677 2025-07-14
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01468883 2024-04-26
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00785291 2022-10-10
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005970 2020-08-14
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00390455 2019-12-20
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
National Cancer Institute (NCI)
Phase 3 Completed
NCT00001806 2019-12-12
Methods in Education for Breast Cancer Genetics
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00513292 2019-01-23
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00590785 2017-08-25
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
National Cancer Institute (NCI)
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003418 2013-12-19
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003577 2013-12-19
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003678 2013-12-19
Tamoxifen in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003893 2013-12-19
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005588 2013-12-19
Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00513916 2013-12-19
Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005581 2013-12-18
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00010140 2013-12-18
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00859989 2013-12-18
A Weight-Loss Program in Helping Obese Black Women Lose Weight
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002579 2013-11-06
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002580 2013-11-06
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002581 2013-11-06
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002755 2013-11-06
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003012 2013-11-06
Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003679 2013-11-06
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003680 2013-11-06
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002720 2013-09-20
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003771 2013-09-20
Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002564 2013-09-17
Nutrition Intervention in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003013 2013-09-17
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00288002 2013-08-26
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00957112 2013-08-26
Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00963729 2013-08-12
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00966888 2013-08-12
Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002455 2013-08-07
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002460 2013-08-07
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00006030 2013-08-07
Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00070278 2013-08-07
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00427245 2013-08-07
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00516425 2013-08-07
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00629278 2013-08-07
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00639366 2013-08-07
Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002544 2013-08-02
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed